Clinical trials of Zydus Cadila’s vaccine will be conducted on children above 5 years of age

Zydus Cadila is a DNA-plasmid based vaccine that is unique compared to the other available vaccines.

The Gujarat-based vaccine producer Zydus Cadila recently announced its DNA-plasmid-based vaccine for Covid-19. Zydus Cadila is currently planning to conduct clinical trials for its Covid vaccine on children above the age of 5 years. The vaccine is currently being reviewed and its approval is pending from the Drugs Controller General of India (DCGI)

Zydus Cadila has currently submitted the approval of its clinical trials on children above 12 years of age. The vaccine data and the application are being reviewed by the DCGI and the decision will be announced in the coming weeks.

The vaccine data suggests that the ZyCoV-D vaccine of Zydus Cadila has an over 66% efficacy rate. This vaccine would be a 3-dose vaccine and is the efficacy is 100% after the 3rd dose. This vaccine is considered unique in terms of it being a DNA-plasmid-based vaccine. This vaccine contains the DNA of the antigens which the body reacts to in terms of an immune response.

As of now, there is not enough data to determine if the vaccine will have any serious side effects. Only time will tell if a DNA-based vaccine is safer than the other vaccines or not.

Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Back to top button
Join WhatsApp group
Skip to content